Literature DB >> 20549370

Can a phenotype for recessive inheritance in breast cancer be defined?

Carolina Ellberg1, Göran Jönsson, Håkan Olsson.   

Abstract

While a dominant inheritance of breast cancer (vertical inheritance) is well known, less is known about a possible recessive inheritance (horizontal inheritance). In a clinical series of 1676 breast cancer patient's family history was scored as vertical (grandmother-aunt-mother-sister-daughter) or horizontal (sister-sister) and related to histopathological tumor type, presence of germline mutations, bilaterality, multifocality, screening, parity, hormone replacement therapy (HRT) use and age at diagnosis. Prognosis was estimated by also adding tumor size, lymph node status, distant metastases and hormone receptor status at diagnosis into a Cox proportional hazard model. Excluding mutations carriers, a horizontal family history (5% of all cases) was significantly associated with tubular tumor type [OR = 3.87(1.44-10.41)]. A vertical family history (23% of all cases) was significantly related to tumor multifocality [OR = 2.30(1.51-3.50)], tumor bilaterality [OR = 2.08(1.44-3.00)] and screening detection [OR = 1.50(1.10-2.05)]. No significant difference in survival could be seen between patients with none, horizontal or vertical family history. However, germline mutation carriers (BRCA1/2, TP53 or CDKN2A, present in 0.95% of the cases) had a significantly worse survival. Screening detected cases, HRT ever users and patients with estrogen receptor positive tumors had a significantly better survival adjusting for age at diagnosis, tumor size, lymph node status and presence of distant metastases at diagnosis. Factors associated with a horizontal family history were found, defining a possible phenotype for a recessive inheritance: tubular breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20549370     DOI: 10.1007/s10689-010-9355-4

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  17 in total

Review 1.  Mammography and breast cancer: the new era.

Authors:  L Tabár; P B Dean
Journal:  Int J Gynaecol Obstet       Date:  2003-09       Impact factor: 3.561

2.  Tubular carcinoma of the breast: association with multicentricity, bilaterality, and family history of mammary carcinoma.

Authors:  M D Lagios; M R Rose; F R Margolin
Journal:  Am J Clin Pathol       Date:  1980-01       Impact factor: 2.493

3.  Segregation analysis of breast cancer from the cancer and steroid hormone study: histologic subtypes.

Authors:  A M Goldstein; C I Amos
Journal:  J Natl Cancer Inst       Date:  1990-12-19       Impact factor: 13.506

4.  Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer.

Authors:  Christopher I Li; Janet R Daling; Kathleen E Malone; Leslie Bernstein; Polly A Marchbanks; Jonathan M Liff; Brian L Strom; Michael S Simon; Michael F Press; Jill A McDonald; Giske Ursin; Ronald T Burkman; Dennis Deapen; Robert Spirtas
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-05       Impact factor: 4.254

5.  Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort.

Authors:  Louise A Brinton; Douglas Richesson; Michael F Leitzmann; Gretchen L Gierach; Arthur Schatzkin; Traci Mouw; Albert R Hollenbeck; James V Lacey
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

6.  Predicting breast cancer risk: implications of a "weak" family history.

Authors:  Elaine Anderson; Jonathan Berg; Roger Black; Nicola Bradshaw; Joyce Campbell; Roseanne Cetnarskyj; Sarah Drummond; Rosemarie Davidson; Jacqueline Dunlop; Alison Fordyce; Barbara Gibbons; David Goudie; Helen Gregory; Kirstie Hanning; Susan Holloway; Mark Longmuir; Lorna McLeish; Vicky Murday; Zosia Miedzybrodska; Donna Nicholson; Pauline Pearson; Mary Porteous; Marta Reis; Sheila Slater; Karen Smith; Elizabeth Smyth; Lesley Snadden; Michael Steel; Diane Stirling; Cathy Watt; Catriona Whyte; Dorothy Young
Journal:  Fam Cancer       Date:  2008-06-17       Impact factor: 2.375

Review 7.  Breast cancer susceptibility: current knowledge and implications for genetic counselling.

Authors:  Tim Ripperger; Dorothea Gadzicki; Alfons Meindl; Brigitte Schlegelberger
Journal:  Eur J Hum Genet       Date:  2008-12-17       Impact factor: 4.246

8.  Segregation analysis of 231 Ashkenazi Jewish families for evidence of additional breast cancer susceptibility genes.

Authors:  David J Kaufman; Terri H Beaty; Jeffery P Struewing
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-10       Impact factor: 4.254

9.  How many more breast cancer predisposition genes are there?

Authors:  D F Easton
Journal:  Breast Cancer Res       Date:  1999-08-23       Impact factor: 6.466

10.  Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients.

Authors:  H Jernström; J Frenander; M Fernö; H Olsson
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

View more
  4 in total

Review 1.  Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications.

Authors:  Eugenia Yiannakopoulou
Journal:  Cell Oncol (Dordr)       Date:  2013-12-04       Impact factor: 6.730

2.  Breast cancer patients with lobular cancer more commonly have a father than a mother diagnosed with cancer.

Authors:  Carolina Ellberg; Håkan Olsson
Journal:  BMC Cancer       Date:  2011-11-28       Impact factor: 4.430

Review 3.  Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis.

Authors:  Alexandra J van den Broek; Marjanka K Schmidt; Laura J van 't Veer; Rob A E M Tollenaar; Flora E van Leeuwen
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

4.  Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer.

Authors:  Rickard Einefors; Ulrika Kogler; Carolina Ellberg; Håkan Olsson
Journal:  Springerplus       Date:  2013-07-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.